Avantor Q4 sales fall 1.4% to $1.66 billion; full-year net loss of $530 million
Avantor reported fourth-quarter and full-year 2025 results on February 11, 2026, with sales down and a full-year GAAP net loss driven by a $785 million goodwill impairment. The company also said it is realigning its reporting into two segments starting in the first quarter of 2026, with recast historical data provided for investors.
Key points
- Q4 2025 net sales were $1.66 billion, down 1.4% from a year earlier; Q4 GAAP diluted EPS was $0.08 versus $0.73 a year earlier, and adjusted EPS was $0.22 versus $0.27.
- Full-year 2025 net sales were $6.55 billion, down 3.4%, with a net loss of $530 million versus net income of $712 million in 2024.
- Full-year 2025 included an impairment charge of $785 million tied to the goodwill of the Distribution reporting unit; adjusted EPS was $0.90 versus $0.99 in 2024.
- Two reportable segments, VWR Distribution & Services and Bioscience & Medtech Products, take effect in Q1 2026; the first 10-Q under the new structure is for the quarter ending March 31, 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 11, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.